Get the Stockscreener App
0.71
2.74%
-0.02
Context Therapeutics Inc stock is traded at $0.71, with a volume of 119.08K.
It is down -2.74% in the last 24 hours and up +13.15% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.73
Open:
$0.7081
24h Volume:
119.08K
Relative Volume:
0.54
Market Cap:
$63.69M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.7802
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
-15.58%
1M Performance:
+13.15%
6M Performance:
-22.26%
1Y Performance:
-68.16%
1-Day Range:
$0.70
$0.7667
1-Week Range:
$0.70
$0.875
52-Week Range:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.71 | 65.48M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
What makes Context Therapeutics Inc. stock price move sharplyShort Term Opportunity Finder with Tools - Newser
Detecting support and resistance levels for Context Therapeutics Inc.Bollinger Band Squeeze and Expansion Analysis - Newser
How Context Therapeutics Inc. stock performs during market volatilityTop Stock Picks with Forecast Accuracy - Newser
What technical models suggest about Context Therapeutics Inc.’s comebackAsset Safety Selection Using Quantitative Analysis - Newser
Custom strategy builders for tracking Context Therapeutics Inc.Entry Optimization Guide with Volume Analysis - Newser
How sentiment analysis helps forecast Context Therapeutics Inc.Technical Analysis of Growth Stock Opportunities - Newser
What analysts say about Context Therapeutics Inc. stock outlookImmediate Entry Point Prediction Strategy - Newser
What are the latest earnings results for Context Therapeutics Inc.Low Risk Growth Plan With Low Risk - jammulinksnews.com
Full technical analysis of Context Therapeutics Inc. stockFree Community Strategy With High Win Rate - Newser
Best data tools to analyze Context Therapeutics Inc. stockSwing Trading Entry Signals Suggest Opportunity Zone - metal.it
How Resilient Is Context Therapeutics Inc. Stock During Economic DownturnsHigh Conviction Stock Long-Term Summary - Newser
Published on: 2025-07-30 01:03:52 - Newser
Published on: 2025-07-30 09:29:19 - beatles.ru
Context Therapeutics Inc. Breakout Confirmed by Volume MetricsTriple Digit Return Stock Predictions Released - metal.it
Why Context Therapeutics Inc. stock attracts strong analyst attentionFree Access to Real-Time Trade Insights - Newser
Context Therapeutics Inc. Rebound Backed by Sentiment ShiftAlpha Focused Technical Trade Signals Gain Attention - metal.it
Context Therapeutics Inc. stock prediction for this weekReliable Setup Screener with Low Risk - Newser
Context Therapeutics Inc. Stock Support and Resistance Levels You Should KnowAI Trend Detection for Entry Timing - Newser
What is the dividend policy of Context Therapeutics Inc. stockUnlock exclusive stock market forecasts - jammulinksnews.com
What is the risk reward ratio of investing in Context Therapeutics Inc. stockCapitalize on market shifts before others do - jammulinksnews.com
What are the technical indicators suggesting about Context Therapeutics Inc.Unlock powerful trading signals and alerts - jammulinksnews.com
How many analysts rate Context Therapeutics Inc. as a “Buy”Breakout stock performance - jammulinksnews.com
Is it the right time to buy Context Therapeutics Inc. stockCapitalize on momentum stocks early - jammulinksnews.com
Is Context Therapeutics Inc. a growth stock or a value stockAchieve breakthrough gains with smart trades - jammulinksnews.com
What institutional investors are buying Context Therapeutics Inc. stockBreakthrough financial growth - jammulinksnews.com
Why is Context Therapeutics Inc. stock attracting strong analyst attentionDiscover stocks with superior performance - jammulinksnews.com
How strong is Context Therapeutics Inc. company’s balance sheetGet exclusive access to expert stock recommendations - jammulinksnews.com
Sectors Driving Future Growth for Context Therapeutics Inc. StockFree Best Stocks to Buy Today - Newser
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN
What drives Context Therapeutics Inc. stock priceGame-changing capital returns - PrintWeekIndia
Context Therapeutics Inc. Stock Analysis and ForecastExceptional trading results - PrintWeekIndia
Is Context Therapeutics Inc. a good long term investmentRapid growth trajectories - PrintWeekIndia
What analysts say about Context Therapeutics Inc. stockBreakthrough profit margins - PrintWeekIndia
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):